2022
Once-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaseline
2019
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care 2019, 42: 1147-1154. PMID: 30728224, PMCID: PMC6973545, DOI: 10.2337/dc18-2316.Peer-Reviewed Original ResearchConceptsType 1 diabetesSodium-glucose cotransporter inhibitorsDiabetic ketoacidosisCotransporter inhibitorsSGLT inhibitorsNear-normal blood glucose levelsOral antidiabetes medicationsBlood glucose levelsAntidiabetes medicationsInhibitor useBlood pressureAbsolute riskMild hyperglycemiaDKA riskGlycemic variabilityConsensus reportGlucose levelsBody weightDrug AdministrationDiabetesType 1U.S. FoodMedical communityKetoacidosisInternational consensus
2017
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes
Tamborlane WV, Polidori D, Argenti D, Di Prospero NA. Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes. Pediatric Diabetes 2017, 19: 649-655. PMID: 29271103, DOI: 10.1111/pedi.12626.Peer-Reviewed Original ResearchConceptsUrinary glucose excretionCanagliflozin 100Type 2 diabetesCanagliflozin 300T2D patientsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPharmacodynamics of canagliflozinSingle daily doseCotransporter 2 inhibitorsTreatment of adultsBody mass indexMaximum plasma concentrationPlasma glucose levelsDose-dependent increasePlasma concentration curveDaily doseGlucose excretionPediatric patientsMass indexPlasma concentrationsRenal thresholdGlucose levelsBody weightPatients
2008
Effect of a Successful Intensive Lifestyle Program on Insulin Sensitivity and Glucose Tolerance in Obese Youth
Shaw M, Savoye M, Cali A, Dziura J, Tamborlane WV, Caprio S. Effect of a Successful Intensive Lifestyle Program on Insulin Sensitivity and Glucose Tolerance in Obese Youth. Diabetes Care 2008, 32: 45-47. PMID: 18840769, PMCID: PMC2606827, DOI: 10.2337/dc08-0808.Peer-Reviewed Original ResearchConceptsIntensive lifestyle programLifestyle programInsulin sensitivityObese youthBody fatGlucose metabolismLarge randomized clinical trialsOral glucose tolerance testGlucose tolerance testRandomized clinical trialsGlucose toleranceObese childrenControl subjectsTolerance testClinical trialsBody compositionBody weightSubject changesGreater decreaseSubjectsFatMetabolismBMIResearch designBright bodies